Abstract
A murine embryonic fibroblast cell line (MEF NF2-/-) was generated to model neurofibromatosis type 2 (NF2), a serious inherited disease for which there is no pharmacotherapeutic cure. Screening of a library of low-molecular-weight bioactive compounds using the experimental cell line MEF NF2-/- and MEF NF2f/f as a control cell line identified two agents, lovastatin and cerulenin, as potential candidates for NF2 pharmacotherapy.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call